N-Phenyl-N'-(1,2,3,4-tetrahydroisochinol-2-yl)-harnstoff | 63237-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: N-Phenyl-N'-(1,2,3,4-tetrahydroisochinol-2-yl)-harnstoff
• 英文别名: 1-(3,4-dihydro-1H-isoquinolin-2-yl)-3-phenyl-urea；1-(3,4-dihydro-1H-isoquinolin-2-yl)-3-phenylurea
• CAS: 63237-77-4
• 化学式: C₁₆H₁₇N₃O
• 分子量: 267.33
• InChiKey: YJQIABGQSLBCMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• PHARMACEUTICAL COMPOSITIONS COMPRISING 3,4- DIHYDROISOQUINOLIN-2(1 H)-YL-3-PHENYLUREA DERIVATIVES HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY
  申请人：Allergan, Inc.

  公开号：EP2646030A1

  公开（公告）日：2013-10-09
• USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES
  申请人：ALLERGAN, INC.

  公开号：EP2964213B1

  公开（公告）日：2020-11-04
• PHARMACEUTICAL COMPOSITIONS COMPRISING 3,4-DIHYDROISOQUINOLIN-2(1H)-YL-3-PHENYLUREA DERIVATIVES HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY
  申请人：Beard Richard L.

  公开号：US20120142726A1

  公开（公告）日：2012-06-07

  The present invention relates to a method of treating a disorder associated with modulation of the FPRL-1 receptor which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising a 3,4-dihydroisoquinolin-2(1H)-yl-3-phenylurea derivative.
• US8507560B2
  申请人：——

  公开号：US8507560B2

  公开（公告）日：2013-08-13
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING 3,4- DIHYDROISOQUINOLIN-2(1 H)-YL-3-PHENYLUREA DERIVATIVES HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES DÉRIVÉS DE LA 3,4-DIHYDRO-ISOQUINOLÉIN-2(1H)-YL-3-PHÉNYLURÉE PRÉSENTANT UNE ACTIVITÉ D'AGONISTE OU D'ANTAGONISTE DE L'ANALOGUE-1 DU RÉCEPTEUR DES PEPTIDES FORMYLÉS (FPRL-1)
  申请人：ALLERGAN INC

  公开号：WO2012074785A1

  公开（公告）日：2012-06-07

  The present invention relates to a method of treating a disorder associated with modulation of the FPRL-1 receptor which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising a 3,4-dihydroisoquinolin-2(1H)-yl-3-phenylurea derivative.